(0.29%) 5 169.50 points
(0.25%) 38 931 points
(0.24%) 18 044 points
(1.08%) $78.95
(0.23%) $2.15
(0.88%) $2 328.90
(2.69%) $27.41
(1.00%) $974.95
(-0.03%) $0.928
(-0.31%) $10.84
(-0.22%) $0.795
(-0.01%) $91.45
2 days till quarter result
(amc 2024-05-08)
Expected move: +/- 6.12%
1.29% $ 15.70
Live Chart Being Loaded With Signals
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy...
Stats | |
---|---|
Dzisiejszy wolumen | 538 283 |
Średni wolumen | 772 466 |
Kapitalizacja rynkowa | 1.43B |
EPS | $0 ( 2024-02-21 ) |
Następna data zysków | ( $-0.970 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.78 |
ATR14 | $0.0200 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Jarrett Jennifer | Sell | 11 551 | Common Stock |
2024-03-18 | Jarrett Jennifer | Sell | 12 153 | Common Stock |
2024-03-18 | Jarrett Jennifer | Sell | 1 296 | Common Stock |
2024-02-26 | Jarrett Jennifer | Sell | 24 555 | Common Stock |
2024-02-27 | Jarrett Jennifer | Sell | 34 070 | Common Stock |
INSIDER POWER |
---|
95.54 |
Last 100 transactions |
Buy: 19 279 293 | Sell: 529 920 |
Wolumen Korelacja
Arcus Biosciences Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Arcus Biosciences Inc Korelacja - Waluta/Towar
Arcus Biosciences Inc Finanse
Annual | 2023 |
Przychody: | $117.00M |
Zysk brutto: | $101.00M (86.32 %) |
EPS: | $-4.15 |
FY | 2023 |
Przychody: | $117.00M |
Zysk brutto: | $101.00M (86.32 %) |
EPS: | $-4.15 |
FY | 2022 |
Przychody: | $112.00M |
Zysk brutto: | $98.00M (87.50 %) |
EPS: | $-3.71 |
FY | 2021 |
Przychody: | $382.88M |
Zysk brutto: | $382.88M (100.00 %) |
EPS: | $0.964 |
Financial Reports:
No articles found.
Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej